Latest News
Lithium Ionic (LTH.V) is up 50% in 3 months, and is moving toward production
Digital Twinning, and how EdgeTI (CTRL.V) is a serious story you’ve never heard of
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
Why Prospera Energy (PEI.V) might be a transformational investment opportunity in Canadian oil & gas
Sparc AI (SPAI.C) completes development of drone advanced target acquisition system
Plurilock (PLUR.V) lands $19 million deal, largest in their history
Medexus Pharmaceuticals (MDP.T) – First Glance with Jody Vance E102
In today’s episode, Jody speaks with Ken d’Entremont, CEO & director of Medexus Pharmaceuticals, a Canadian-based company focused on improving and fast-tracking already-approved specialty drugs into the Canadian and American markets.
Enjoy!
Related Posts
Potential of Medexus Pharmaceuticals: Chris Parry gets into what investors are missing
Medexus Pharma (MDP.TO) Breaks Records: A Deep Dive into Quarterly Earnings, Portfolio Growth, and Future Opportunities
Medexus Pharmaceuticals (MDP): A Roller Coaster Ride to Success
Medexus Pharmaceuticals Sets New Revenue Records and Continues Expansion with Innovative Products and Financing
Medexus Pharmaceuticals (MDP.T) deals with its debentures
Medexus CEO (MDP.T) on creating Canada’s specialty pharma success story
More on MDP.T
Medexus Pharmaceuticals (MDP.T) – Three Minute Hits Video
Medexus Pharma (MDP.T) – Investor Roundtable Video #3
Medexus Pharma (MDP.T) – Three Minute Hits Video
Biotech Sector Roundup – Investor Roundtable Video
Medexus Pharma’s (MDP.T) specialty pharma investment value on the rise